The moment that matters usually starts as a data point.

Explore the dashboard intel.cratonmeridian.com/pharma/CT8K/density.html See where your category sits.

We built this to understand the pharma landscape for our own work: which categories are crowding, which trials just moved, which companies are entering the window where what AI says about them starts to count. It got useful enough that we opened the public layer to everyone.

The Density Atlas: every tracked therapeutic condition placed by three-year growth and sized by trial volume, with Obesity highlighted as a fast-growing outlier.
The Density Atlas. Every tracked condition placed by three-year growth, sized by trial volume. Obesity, far right, is up 206 percent in three years.

Two public records, every study on ClinicalTrials.gov and the SEC 8-K filings companies make around the events that move them, matched and scored into one monitor. 766 companies, 1,000+ therapeutic areas, 9 years.

Two data layers: Clinical Trial Data from ClinicalTrials.gov and SEC 8-K Filing Data, with headline counts.
Two signals, one monitor: ClinicalTrials.gov studies and SEC 8-K filings, matched and scored.

See which therapeutic areas are crowded and which are wide open, and watch the newest trial-and-filing signals as they land.

The Density Atlas arranged into cohorts: declining, flat, and rising therapeutic areas.
The same conditions, sorted into declining, flat, and rising cohorts.

Two public signals, free for anyone to explore. The closer read, what AI tells investors, physicians, and patients about a single company, is the work we do with our clients.

Andrew David Linde
Founder and Principal
Craton Meridian™ | AI Integrity™

Explore the dashboard intel.cratonmeridian.com/pharma/CT8K/density.html See where your category sits.